Orphan drug specialist Horizon looks to double down on its gout expertise with acquired rights to Arrowhead's RNAi med
Horizon Therapeutics has made a name for taking orphan drugs once left on the scrap heap and spinning them into approved therapies. Along the way, the biotech has picked up an expertise in gout with bestselling Krystexxa, and now it’s looking to double down in that space with a licensing deal for an Arrowhead drug.
Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals’ ARO-XDH, an investigational RNAi therapy for uncontrolled gout, the partners said Monday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 117,700+ biopharma pros reading Endpoints daily — and it's free.